PRF Technologies (PRFX) Net Income Growth (3y) (2023 - 2024)
PRF Technologies (PRFX) Net Income Growth (3y) (2023 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 51.28% |
| 3 | Zoetis | 32.39 Bn | 30.45 Bn | 1.62 Bn | 2.94% |
| 4 | Takeda Pharmaceutical | 27.59 Bn | 23.53 Bn | 4.39 Bn | -62.58% |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 4.50% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.46 Bn | 1.16 Bn | -7.75% |
| 8 | Neurocrine Biosciences | 18.00 Bn | 16.69 Bn | 800.70 Mn | 66.11% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -17.90% |
| 10 | PRF Technologies | 738,689.21 | -3.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 72.45% |
| Mar 31, 2024 | -39.21% |
| Dec 31, 2023 | -37.11% |
| Sep 30, 2023 | -67.91% |
| Jun 30, 2023 | -59.86% |
| Mar 31, 2023 | 55.79% |